Literature DB >> 15642816

Health- and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery: Submacular Surgery Trials Report No. 5.

.   

Abstract

OBJECTIVES: To (1) summarize vision-targeted and general health-related quality-of-life scores at baseline and quantify the effect of the ophthalmic problem, (2) evaluate the strength of relations between visual acuity and interview scores, and (3) compare scores for patients who also had choroidal neovascular lesions in the fellow eye (bilateral cases) with those of patients who had choroidal neovascularization in only the study eye (unilateral cases) at time of enrollment in a randomized trial of surgical removal of subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or of idiopathic origin.
DESIGN: Eligible patients had subfoveal choroidal neovascularization (including some classic choroidal neovascularization) and a visual acuity of 20/50 to 20/800 (Snellen equivalent), inclusive, in the eye to be assigned randomly to surgery or observation. Interviews that incorporated the 39-item version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) and 2 other instruments were conducted by telephone by trained interviewers before patients enrolled and were assigned randomly to surgery or observation. Information from baseline clinical examinations and fluorescein angiograms interpreted centrally by masked readers was used to classify patients as unilateral or bilateral cases and to provide potential explanations for variability of interview responses using linear regression models.
RESULTS: The median overall NEI-VFQ score was 75 (interquartile range, 60-84). The median scores on individual subscales ranged from 55 (general vision) to 100 (color vision). The visual acuity of the better-seeing eye accounted for much of the variability in scores on most NEI-VFQ subscales; a 3-line difference in visual acuity was associated with a 10-point or greater difference in scores on 5 subscales after adjustment for other characteristics of patients and eyes. Scores on most scales of all 3 instruments differed between unilateral cases (n = 167) and bilateral cases (n = 58). Even after adjustment for visual acuity and reading speed of the better-seeing eye, age, gender, and scores on the other instruments, scores on the NEI-VFQ near and distance activities subscales differed by almost 13 and 10 points, respectively, between unilateral and bilateral cases. Neither age nor gender was an important independent explanatory variable for NEI-VFQ scores.
CONCLUSIONS: Unilateral and bilateral cases had vision-targeted health-related quality-of-life scores worse than those published for a reference population without eye disease. Furthermore, despite younger age, better visual acuity, and better short-term visual prognosis, bilateral cases had NEI-VFQ scores at baseline similar to those published for 2 groups of patients with age-related macular degeneration. Unidentified factors, in addition to the visual acuity of the better-seeing eye, affected patients' perceptions of visual function.

Entities:  

Mesh:

Year:  2005        PMID: 15642816      PMCID: PMC1256027          DOI: 10.1001/archopht.123.1.78

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

1.  Consistency between visual acuity scores obtained at different test distances: theory vs observations in multiple studies.

Authors:  Li Ming Dong; Barbara S Hawkins; Marta J Marsh
Journal:  Arch Ophthalmol       Date:  2002-11

2.  SPECIFIC OCULAR UVEAL LESIONS IN PATIENTS WITH EVIDENCE OF HISTOPLASMOSIS.

Authors:  T E VAN METRE; A E MAUMENEE
Journal:  Arch Ophthalmol       Date:  1964-03

3.  Development of the 25-item National Eye Institute Visual Function Questionnaire.

Authors:  C M Mangione; P P Lee; P R Gutierrez; K Spritzer; S Berry; R D Hays
Journal:  Arch Ophthalmol       Date:  2001-07

4.  Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-09

5.  Follow-up study of presumed ocular histoplasmosis.

Authors:  J D Gass; C P Wilkinson
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1972 May-Jun

6.  An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States.

Authors:  L B Edwards; F A Acquaviva; V T Livesay; F W Cross; C E Palmer
Journal:  Am Rev Respir Dis       Date:  1969-04

7.  Effect of order of administration of health-related quality of life interview instruments on responses.

Authors:  Ashley L Childs
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

8.  Blindness from presumed ocular histoplasmosis in Tennessee.

Authors:  S S Feman; S F Podgorski; M K Penn
Journal:  Ophthalmology       Date:  1982-12       Impact factor: 12.079

9.  Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  1983-09

10.  Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1996-06
View more
  9 in total

1.  Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation.

Authors:  Jonathan W Kowalski; Anne M Rentz; John G Walt; Andrew Lloyd; Jeff Lee; Tracey A Young; Wen-Hung Chen; Neil M Bressler; Paul Lee; John E Brazier; Ron D Hays; Dennis A Revicki
Journal:  Qual Life Res       Date:  2011-08-04       Impact factor: 4.147

2.  Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.

Authors:  Barbara S Hawkins; Neil M Bressler; Susan B Bressler; Frederick H Davidorf; John C Hoskins; Marta J Marsh; Päivi H Miskala; Maryann Redford; Paul Sternberg; Matthew A Thomas; Cynthia A Toth
Journal:  Arch Ophthalmol       Date:  2004-11

3.  Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10.

Authors:  Barbara S Hawkins; Päivi H Miskala; Eric B Bass; Neil M Bressler; Ashley L Childs; Carol M Mangione; Marta J Marsh
Journal:  Arch Ophthalmol       Date:  2004-11

4.  The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project.

Authors:  Traci E Clemons; Mark C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Maria Figueroa; Molly W Harrington
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

5.  Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation.

Authors:  Lin Zhou; Yi-Qiao Xing; Tuo Li; Yin Li; Xiu-Sheng Song; Jia-Zhang Li
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

6.  The chronic care for age-related macular degeneration study (CHARMED): study protocol for a randomized controlled trial.

Authors:  Anja Frei; Katja Woitzek; Mathyas Wang; Ulrike Held; Thomas Rosemann
Journal:  Trials       Date:  2011-10-11       Impact factor: 2.279

Review 7.  Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration.

Authors:  Amisha Gupta; Jessica Lam; Peter Custis; Stephen Munz; Donald Fong; Marguerite Koster
Journal:  Cochrane Database Syst Rev       Date:  2018-05-30

8.  Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version.

Authors:  Yoshimi Suzukamo; Tetsuro Oshika; Mitsuko Yuzawa; Yoshihiro Tokuda; Atsuo Tomidokoro; Kotaro Oki; Carol M Mangione; Joseph Green; Shunichi Fukuhara
Journal:  Health Qual Life Outcomes       Date:  2005-10-26       Impact factor: 3.186

9.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.